The NeoTYPE Melanoma Tumor Profile analyzes 28 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of all results to help guide treatment decisions. If Pan-TRK IHC is expressed or equivocal, NTRK NGS Fusion Profile for NTRK1 fusions, NTRK2 fusions, and NTRK3 fusions will be added by reflex.
NGS (22 genes + 2 biomarkers): AKT1, BAP1, BRAF, CDK4, CDKN2A, CTNNB1, EGFR, ERBB2, ERBB4, FGFR1, FGFR2, FGFR3, GNA11, GNAQ, KIT, Microsatellite Instability (MSI), NBN, NF1, NRAS, PDGFRA, SMO, SRC, TERT Promoter, Tumor Mutation Burden (TMB)
FISH (1 FISH): PTEN (tech-only available)
IHC (2 biomarkers): PD-L1 28-8, Pan-TRK (tech-only available for PD-L1)
The NeoTYPE Melanoma Profile assesses the most commonly-mutated driver mutations in primary or metastatic melanoma to determine prognosis and identify established and clinical trial-based therapeutic options. This NeoTYPE Profile is for histologically-confirmed melanoma and is not appropriate for differentiating melanoma from ambiguous melanocytic lesions. For that indication, please see the separate listing for the MelanoSITE™ Melanoma FISH Panel.
- FFPE tissue: Paraffin block (preferred). Please use 10% buffered formalin fixative. Do not use zinc fixatives.
Use cold pack for transport, making sure cold pack is not in direct contact with specimen. All slides can be packed at room temperature.